CN102526000A - Dexibuprofen slow-release capsule and production method thereof - Google Patents
Dexibuprofen slow-release capsule and production method thereof Download PDFInfo
- Publication number
- CN102526000A CN102526000A CN201210023257XA CN201210023257A CN102526000A CN 102526000 A CN102526000 A CN 102526000A CN 201210023257X A CN201210023257X A CN 201210023257XA CN 201210023257 A CN201210023257 A CN 201210023257A CN 102526000 A CN102526000 A CN 102526000A
- Authority
- CN
- China
- Prior art keywords
- coatings
- micropill
- dexibuprofen
- capsule
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 title claims abstract description 96
- 239000002775 capsule Substances 0.000 title claims abstract description 74
- 229960003428 dexibuprofen Drugs 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 238000000576 coating method Methods 0.000 claims abstract description 180
- 239000011248 coating agent Substances 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000008188 pellet Substances 0.000 claims abstract description 19
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 18
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 18
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000008117 stearic acid Substances 0.000 claims abstract description 18
- 238000013268 sustained release Methods 0.000 claims description 51
- 239000012730 sustained-release form Substances 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 39
- 238000007789 sealing Methods 0.000 claims description 33
- 239000012530 fluid Substances 0.000 claims description 18
- 229920003081 Povidone K 30 Polymers 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000011247 coating layer Substances 0.000 abstract 9
- 239000010410 layer Substances 0.000 abstract 5
- 238000002955 isolation Methods 0.000 abstract 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000011162 core material Substances 0.000 description 42
- 229920002472 Starch Polymers 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 229960004793 sucrose Drugs 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a dexibuprofen slow-release capsule. Pellets are filled in the capsule, each pellet consists of a pellet core and four layers of materials wrapped outside the pellet core, the four layers of materials are sequentially an inner isolation layer, a first coating layer, a second coating layer and a third coating layer from inside to outside, and the pellet core, the inner isolation layer, the first coating layer, the second coating layer and the third coating layer respectively have the following compositions: the pellet core is prepared by medicine auxiliary materials, the inner isolation layer is stearic acid, the first coating layer is a coating mixture, the second coating layer comprises the coating mixture and the stearic acid, the third coating layer is the coating mixture, and the coating mixture consists of dexibuprofen and polyvidone K30. The invention also provides a production method of the dexibuprofen slow-release capsule. Compared with an ordinary capsule, the dexibuprofen slow-release capsule disclosed by the invention has the same absorption degree, but the dexibuprofen blood maximum concentration (Cmax) of the dexibuprofen slow-release capsule disclosed by the invention in human bodies is lower, the maximum time (Tmax) from the administration to the blood Cmax reaching is longer, and a good slow release effect is realized.
Description
Technical field
The present invention relates to a kind of Dexibuprofen sustained-release capsule and production method thereof.
Background technology
(S)-ibuprofen is S (+)-isomer of ibuprofen, and activity was 160 times of levo form in Austria listing in 1994,1.6 times of racemic modification.Ibuprofen is made up of the d-isomer and the levo form of equivalent; Clinical practice has 30 years history; Be one of the most general NSAIDs class medicine of clinical use, be considered to safest nonsteroidal antiinflammatory drug (NSAIDs), 1984 is the OTC medicine by drugs approved by FDA.Clinical data shows that (S)-ibuprofen is faster than racemic ibuprofen onset; The mechanism of action is consistent, but pharmacological action is better, is a kind of non-selective cyclooxygenase (COX) inhibitor; Be widely used in the treatment atrophic diseases, and multiple pain such as articular muscle is felt sorry, headache, dysmenorrhea.
Owing to use (S)-ibuprofen to overcome ibuprofen some shortcomings aspect use pharmacodynamics and pharmacokinetics, the external existing trend that substitutes racemic ibuprofen with (S)-ibuprofen.Clinical research shows that the dosage of (S)-ibuprofen is that 75% o'clock of racemic ibuprofen can reach identical or better clinical effect.
At present, the dosage form of (S)-ibuprofen has tablet, suppository, capsule and four kinds of dosage forms of oral suspensions, the research of the release dosage form that do not slow yet.Because the half-life of (S)-ibuprofen is about 2 hours, absorbs rapidly through gastrointestinal tract, accretion rate is fast, and the half-life is shorter, need take medicine every day 3～4 times.Medicining times is many, has not only increased the weight of patient's burden, and the concentration change of (S)-ibuprofen is big in the patient blood, and side effect is also big.
Summary of the invention
Problem to be solved by this invention provides and a kind ofly can reduce medicining times, reduces the Dexibuprofen sustained-release capsule and the production method thereof of (S)-ibuprofen blood medicine peak value.
The capsular technical scheme of Dexibuprofen sustained-release of the present invention is: a kind of Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is a pharmaceutic adjuvant; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is made up of (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30.
The capsular fine pellet core of Dexibuprofen sustained-release of the present invention is slow releasing capsule a kind of pharmaceutic adjuvant commonly used, the spheroidal particle that can process by sucrose and starch, and as the core material of this preparation, a carrier function.Cane sugar content is 62.5% ~ 91.5% in the fine pellet core, and all the other are starch.
Dexibuprofen sustained-release capsule of the present invention is suitable with the conventional capsule degree of absorption, still, and Dexibuprofen sustained-release capsule of the present invention (S)-ibuprofen blood medicine peak value (C in vivo
Max) lower, from taking the time (T that reaches blood medicine peak value
Max) longer.
Slow releasing capsule of the present invention and general capsule are carried out clinical bioavailability and bioequivalence comparison; Find out capsular slow release effect of the present invention more easily; Relatively capsule of the present invention is called and receives test preparation, will be used for being called the reference capsule as capsule relatively; Comparative approach comprises that single-dose compares and multiple dosing compares.The reference capsule is commercially available conventional capsule, and its composition is (S)-ibuprofen, starch and sugar.
Single-dose compares: behind single-dose 450 mg, tried the capsular AUC of capsule and reference
0-24Be respectively 87.32ug.h/ml and 76.56 ug.h/ml; AUC
0-∞Be respectively 88.36ug.h/ml and 77.74 ug.h/ml; C
MaxBe respectively 13.93 ug/ml and 19.53 ug/ml; T
MaxBe respectively 3.95h and 1.80h; t
1/2Be respectively 2.75 ± 0.80 h and 2.73 ± 0.92 h.Judge according to The above results, tried capsular degree of absorption and be higher than the reference capsule, and tried capsule C
MaxObviously reduce T
MaxObviously prolong, thus decidable two preparation bioequivalences, and tried capsule and have the slow release dynamic characteristic.
Multiple dosing compares: continuous several times oral test capsule, each 225mg, every day 2 times, totally 7 days; The (S)-ibuprofen capsule, each 150mg, every day 3 times, totally 7 days.Acquisition is tried the parameter A UC that capsule and reference capsule reach limit
SsBe respectively 74.73ug.h/ml and 75.46 ug.h/ml; AUC
0-∞Be respectively 79.01ug.h/ml and 81.57ug.h/ml; C
MaxBe respectively 6.62ug/ml and 6.78ug/ml; T
MaxBe respectively 4.50 and 2.39h; C
MinBe respectively 1.03ug/ml and 1.12ug/ml; C
SsBe respectively 3.11ug/ml and 3.14ug/ml; DF is respectively 1.83 and 1.81.Judge according to The above results, tried capsule and the reference capsule is suitable at the degree of absorption that the continuous several times administration reaches under the limit, the blood concentration fluctuation degree that is tried capsule administration every day 2 times and administration every day of reference capsule 3 times is comparatively approaching, is tried capsular T
MaxObviously prolong,, and tried capsule and have the slow release dynamic characteristic so decidable two brood lac Tibetan household slave's things are equivalent.
The weight ratio of coating mixture is (80 ~ 88) among the capsular coatings I of Dexibuprofen sustained-release of the present invention, coatings II and the coatings III: (3 ~ 8): 10.
Coating solution and stearic weight ratio are (1.8 ~ 2.2) among the capsular coatings II of Dexibuprofen sustained-release of the present invention: 1.
The weight ratio of (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30 is (25 ~ 35) in the capsular coating mixture of Dexibuprofen sustained-release of the present invention: (1).
The weight of (S)-ibuprofen is 209.25 ~ 240.75mg in every Dexibuprofen sustained-release capsule of the present invention.
The particle diameter of the capsular fine pellet core of Dexibuprofen sustained-release of the present invention is 600 ~ 710um.
The present invention also provides a kind of above-mentioned Dexibuprofen sustained-release capsular production method, and this method comprises the steps:
(1) fine pellet core is added in the fluid bed, start fluid bed, spray sealing coat solution in the past fluid bed, dry then, the ball core of sealing coat was called micropill I in gained was surrounded by, and above-mentioned interior sealing coat solution is ethanol and stearic mixed solution;
(2) in the fluid bed that contains micropill I, spray coating solution, must be surrounded by the micropill of coatings I, after drying, cross 16 orders and 24 mesh sieves, collect 16 orders, be called micropill II to the micropill between 24 orders;
(3) in the fluid bed that contains micropill II, spray coating solution and stearic mixture, gained is surrounded by the micropill of coatings II, after drying, crosses 14 orders and 24 mesh sieves, collects 14 orders to the micropill between 24 orders, is called micropill III;
(4) in the fluid bed that contains micropill III, spray coating solution, after the coating solution drying, must be surrounded by the micropill of coatings III, be called micropill IV;
(5) gained micropill IV in the step (4) is added Capsules, promptly get the Dexibuprofen sustained-release capsule; Above-mentioned coating solution is the alcoholic solution that contains (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30.
Alcoholic solution in the coating solution can volatilize in dry run, and the remaining solid that contains (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30 is the coating mixture.
In the capsular production method of above-mentioned Dexibuprofen sustained-release, the composition of each composition and proportioning can be with reference to the Dexibuprofen sustained-release capsules of this aforementioned invention, that is:
The weight ratio of the coating solution that sprays in step (2), (3) and (4) is (80 ~ 88): (3 ~ 8): 10.
Coating solution and stearic weight ratio are (1.8 ~ 2.2) in the step (3): 1.
In the capsular production method of Dexibuprofen sustained-release of the present invention, the weight ratio of (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30 is (25 ~ 35) in the coating solution: (1).
The weight of (S)-ibuprofen is 209.25 ~ 240.75mg/ capsules in the Dexibuprofen sustained-release capsule that the capsular production method of the Dexibuprofen sustained-release of invention obtains.
The specific embodiment
Embodiment 1:
The Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is the pharmaceutic adjuvant of being made up of sucrose and starch; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is that (S)-ibuprofen and the 30 POVIDONE K 30 BP/USP 30 of 25:1 formed by weight ratio; The weight ratio of coating mixture is 85:3:10 among above-mentioned coatings I, coatings II and the coatings III; Coating solution and stearic weight ratio are 2:1 among the coatings II; The weight of (S)-ibuprofen is 208mg in every above-mentioned Dexibuprofen sustained-release capsule, and the particle diameter of the capsular fine pellet core of above-mentioned Dexibuprofen sustained-release is 600um.
Embodiment 2:
The Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is the pharmaceutic adjuvant of being made up of sucrose and starch; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is that (S)-ibuprofen and the 30 POVIDONE K 30 BP/USP 30 of 30:1 formed by weight ratio; The weight ratio of coating mixture is 80:4:10 among above-mentioned coatings I, coatings II and the coatings III; Coating solution and stearic weight ratio are 1.8:1 among the coatings II; The weight of (S)-ibuprofen is 220mg in every above-mentioned Dexibuprofen sustained-release capsule, and the particle diameter of the capsular fine pellet core of above-mentioned Dexibuprofen sustained-release is 680um.
Embodiment 3:
The Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is the pharmaceutic adjuvant of being made up of sucrose and starch; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is that (S)-ibuprofen and the 30 POVIDONE K 30 BP/USP 30 of 35:1 formed by weight ratio; The weight ratio of coating mixture is 88:6:10 among above-mentioned coatings I, coatings II and the coatings III; Coating solution and stearic weight ratio are 2.2:1 among the coatings II; The weight of (S)-ibuprofen is 241mg in every above-mentioned Dexibuprofen sustained-release capsule, and the particle diameter of the capsular fine pellet core of above-mentioned Dexibuprofen sustained-release is 650um.
Embodiment 4:
The Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is the pharmaceutic adjuvant of being made up of sucrose and starch; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is that (S)-ibuprofen and the 30 POVIDONE K 30 BP/USP 30 of 33:1 formed by weight ratio; The weight ratio of coating mixture is 85:6:10 among above-mentioned coatings I, coatings II and the coatings III; Coating solution and stearic weight ratio are 2.1:1 among the coatings II; The weight of (S)-ibuprofen is 230mg in every above-mentioned Dexibuprofen sustained-release capsule, and the particle diameter of the capsular fine pellet core of above-mentioned Dexibuprofen sustained-release is 700um.
Embodiment 5:
The Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is the pharmaceutic adjuvant of being made up of sucrose and starch; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is that (S)-ibuprofen and the 30 POVIDONE K 30 BP/USP 30 of 31:1 formed by weight ratio; The weight ratio of coating mixture is 82:8:10 among above-mentioned coatings I, coatings II and the coatings III; Coating solution and stearic weight ratio are 1.9:1 among the coatings II; The weight of (S)-ibuprofen is 208mg in every above-mentioned Dexibuprofen sustained-release capsule, and the particle diameter of the capsular fine pellet core of above-mentioned Dexibuprofen sustained-release is 710um.
Embodiment 6:
The Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is the pharmaceutic adjuvant of being made up of sucrose and starch; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is that (S)-ibuprofen and the 30 POVIDONE K 30 BP/USP 30 of 27:1 formed by weight ratio; The weight ratio of coating mixture is 82:3:10 among above-mentioned coatings I, coatings II and the coatings III; Coating solution and stearic weight ratio are 2:1 among the coatings II; The weight of (S)-ibuprofen is 228mg in every above-mentioned Dexibuprofen sustained-release capsule, and the particle diameter of the capsular fine pellet core of above-mentioned Dexibuprofen sustained-release is 670um.
Embodiment 7:
The capsular production method of a kind of Dexibuprofen sustained-release, this method comprises the steps:
(1) fine pellet core is added in the fluid bed, start fluid bed, spray sealing coat solution in the past fluid bed, dry then, the ball core of sealing coat was called micropill I in gained was surrounded by, and above-mentioned interior sealing coat solution is ethanol and stearic mixed solution;
(2) in the fluid bed that contains micropill I, spray coating solution, must be surrounded by the micropill of coatings I, after drying, cross 16 orders and 24 mesh sieves, collect 16 orders, be called micropill II to the micropill between 24 orders;
(3) in the fluid bed that contains micropill II, spray coating solution and stearic mixture, gained is surrounded by the micropill of coatings II, after drying, crosses 14 orders and 24 mesh sieves, collects 14 orders to the micropill between 24 orders, is called micropill III;
(4) in the fluid bed that contains micropill III, spray coating solution, after the coating solution drying, must be surrounded by the micropill of coatings III, be called micropill IV;
(5) gained micropill IV in the step (4) is added Capsules, promptly get the Dexibuprofen sustained-release capsule; Above-mentioned coating solution is the alcoholic solution that contains (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30.
The weight ratio of the coating solution that sprays in step (2), (3) and (4) is (80 ~ 88): (3 ~ 8): 10.
Coating solution and stearic weight ratio are (1.8 ~ 2.2) in the step (3): 1.
In the capsular production method of Dexibuprofen sustained-release of the present invention, the weight ratio of (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30 is (25 ~ 35) in the coating solution: (1).
The weight of (S)-ibuprofen is 209.25 ~ 240.75mg/ capsules in the Dexibuprofen sustained-release capsule that the capsular production method of the Dexibuprofen sustained-release of invention obtains.
Claims (7)
1. Dexibuprofen sustained-release capsule; Be filled with micropill in the capsule; Micropill is made up of ball core four layer materials outer with being wrapped in the ball core; Four layer materials are followed successively by from inside to outside: interior sealing coat, coatings I, coatings II and coatings III, and ball core, interior sealing coat, coatings I, coatings II and coatings III composition separately are following: the ball core is a pharmaceutic adjuvant; Interior sealing coat is a stearic acid; Coatings I is the coating mixture; Coatings II contains coating mixture and stearic acid; Coatings III is the coating mixture; Said coating mixture is made up of (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30.
2. according to the described Dexibuprofen sustained-release capsule of claim 1, it is characterized in that: among said coatings I, coatings II and the coatings III, the weight ratio of coating mixture is (80 ~ 88): (3 ~ 8): 10.
3. according to the described Dexibuprofen sustained-release capsule of claim 1, it is characterized in that: coating mixture and stearic weight ratio are (1.8 ~ 2.2) among the said coatings II: 1.
4. according to the described Dexibuprofen sustained-release capsule of claim 1, it is characterized in that: the weight ratio of (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30 is (25 ~ 35) in the said total coated mixture: 1.
5. according to the described Dexibuprofen sustained-release capsule of claim 1, it is characterized in that: the weight of (S)-ibuprofen is 208 ~ 241mg in every capsules.
6. according to the capsular production method of the described Dexibuprofen sustained-release of claim 1, it is characterized in that: the particle diameter of said fine pellet core is 600 ~ 710um.
7. according to the capsular production method of any one described Dexibuprofen sustained-release in the claim 1 to 7, this method comprises the steps:
(1) fine pellet core is added in the fluid bed, start fluid bed, spray sealing coat solution in the past fluid bed, dry then, the ball core of sealing coat was called micropill I in gained was surrounded by, and above-mentioned interior sealing coat solution is ethanol and stearic mixed solution;
(2) in the fluid bed that contains micropill I, spray coating solution, gained is surrounded by the micropill of coatings I, after drying, crosses 16 orders and 24 mesh sieves, collects 16 orders to the micropill between 24 orders, is called micropill II;
(3) in the fluid bed that contains micropill II, spray coating solution and stearic mixture, gained is surrounded by the micropill of coatings II, after drying, crosses 14 orders and 24 mesh sieves, collects 14 orders to the micropill between 24 orders, is called micropill III;
(4) in the fluid bed that contains micropill III, spray coating solution, after the coating solution drying, must be surrounded by the micropill of coatings III, be called micropill IV;
(5) gained micropill IV in the step (4) is added Capsules, promptly get the Dexibuprofen sustained-release capsule; Above-mentioned the coating solution described in steps is the alcoholic solution that contains (S)-ibuprofen and 30 POVIDONE K 30 BP/USP 30.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210023257 CN102526000B (en) | 2012-02-02 | 2012-02-02 | Dexibuprofen slow-release capsule and production method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210023257 CN102526000B (en) | 2012-02-02 | 2012-02-02 | Dexibuprofen slow-release capsule and production method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526000A true CN102526000A (en) | 2012-07-04 |
| CN102526000B CN102526000B (en) | 2013-05-01 |
Family
ID=46334833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210023257 Expired - Fee Related CN102526000B (en) | 2012-02-02 | 2012-02-02 | Dexibuprofen slow-release capsule and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526000B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546801A (en) * | 2015-02-03 | 2015-04-29 | 孙巧玲 | Sustained-release capsule containing ibuprofen despinner or dextroisomer and preparation process of sustained-release capsule |
| CN109966268A (en) * | 2019-04-04 | 2019-07-05 | 吉林市吴太感康药业有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN110314152A (en) * | 2018-11-27 | 2019-10-11 | 西安圣雪沙药物开发有限公司 | A kind of ibuprofen slow-release micro pill capsule and preparation method thereof |
| CN110327309A (en) * | 2019-07-17 | 2019-10-15 | 珠海润都制药股份有限公司 | A kind of ibuprofen slow-release piller that viscous ball does not occur |
| CN110755396A (en) * | 2019-12-06 | 2020-02-07 | 北京悦康科创医药科技股份有限公司 | Ibuprofen sustained-release pellet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269041A (en) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | Dexibuprofen sustained-release dropping pill and preparation method thereof |
| CN101467989A (en) * | 2007-12-27 | 2009-07-01 | 北京德众万全医药科技有限公司 | Sustained-release pellet containing ibuprofen |
-
2012
- 2012-02-02 CN CN 201210023257 patent/CN102526000B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101467989A (en) * | 2007-12-27 | 2009-07-01 | 北京德众万全医药科技有限公司 | Sustained-release pellet containing ibuprofen |
| CN101269041A (en) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | Dexibuprofen sustained-release dropping pill and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 毛世瑞等: "聚维酮在药剂学中的应用", 《沈阳药科大学学报》, vol. 14, no. 3, 31 July 1997 (1997-07-31), pages 224 - 230 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546801A (en) * | 2015-02-03 | 2015-04-29 | 孙巧玲 | Sustained-release capsule containing ibuprofen despinner or dextroisomer and preparation process of sustained-release capsule |
| CN104546801B (en) * | 2015-02-03 | 2017-07-18 | 常州市第四制药厂有限公司 | A kind of spansule and its preparation technology containing brufen raceme or d-isomer |
| CN110314152A (en) * | 2018-11-27 | 2019-10-11 | 西安圣雪沙药物开发有限公司 | A kind of ibuprofen slow-release micro pill capsule and preparation method thereof |
| CN110314152B (en) * | 2018-11-27 | 2021-03-26 | 西安圣雪沙药物开发有限公司 | Ibuprofen sustained-release pellet capsule and preparation method thereof |
| CN109966268A (en) * | 2019-04-04 | 2019-07-05 | 吉林市吴太感康药业有限公司 | A kind of preparation method of ibuprofen sustained release capsules |
| CN110327309A (en) * | 2019-07-17 | 2019-10-15 | 珠海润都制药股份有限公司 | A kind of ibuprofen slow-release piller that viscous ball does not occur |
| CN110327309B (en) * | 2019-07-17 | 2023-02-10 | 珠海润都制药股份有限公司 | Ibuprofen sustained-release pellet without pill sticking |
| CN110755396A (en) * | 2019-12-06 | 2020-02-07 | 北京悦康科创医药科技股份有限公司 | Ibuprofen sustained-release pellet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526000B (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2072840C1 (en) | Solid medicinal form of the prolonged action for cardiovascular disease treatment | |
| CN102526000B (en) | Dexibuprofen slow-release capsule and production method thereof | |
| CN103417505B (en) | There is huperzine controlled release preparation of two-phase drug release behavior and preparation method thereof | |
| EP2440189B1 (en) | Reduction of opioid blood fluctuations | |
| WO2011063732A1 (en) | Paliperidone double-layered osmotic pump controlled release tablet and preparation method thereof | |
| TW200427448A (en) | Controlled release preparations comprising tramadol and topiramate | |
| CN101257893A (en) | Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof | |
| CN101987091A (en) | Venlafaxine hydrochloride sustained-release pellet capsules | |
| HRP20000213A2 (en) | Extended release formulation | |
| CN103189054A (en) | Sustained-release pellets containing tacrolimus as an active ingredient | |
| CN101647789A (en) | Levetiracetam slow release pellet capsule preparation and preparation method thereof | |
| CN1682719B (en) | Enteric soluble coating slow releasing tablet containing huperzine A and preparing method | |
| CN102048701B (en) | Pitavastatin calcium enteric sustained-release micropill preparation and preparation method thereof | |
| CN101095681B (en) | Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same | |
| CN103908443A (en) | Propafenone hydrochloride sustained-release capsule and preparation method thereof | |
| CN102626428A (en) | Ginkgo leaf extract osmotic pump controlled-release preparation and preparation method thereof | |
| FR2778848A1 (en) | Multiparticulate pharmaceutical composition that give controlled release of active material commencing 4 - 8 hours after administration, having neutral core and two different polymeric coating layers | |
| CN105769773A (en) | Loxoprofen sodium sustained-release pellet | |
| CN101081217A (en) | Slow-release small pill prparation containing huperzine A and method for making same | |
| CN110251473A (en) | Hydroxyl piperazine pyrrone oral slow-releasing preparation | |
| CN101120931A (en) | Bezafibrate sustained-release composition | |
| CN106924205A (en) | A kind of sustained release preparation containing Baricitinib | |
| CN102697761B (en) | Ibuprofen slow release solid composition and preparation method thereof | |
| CN101756981B (en) | Brufen loratadine pseudoephedrine release preparation and preparation method thereof | |
| CN104856971B (en) | A kind of pulse dual-release preparation and the preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130501 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |